RTP Mobile Logo
Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Application of Immune Checkpoint Inhibition in the Management of Metastatic Lung Cancer
Released December 2018

Proceedings from a CME symposium held at the 2018 SITC Annual Meeting. Featuring perspectives from Drs Edward B Garon, Giuseppe Giaccone, Roy S Herbst and Vali A Papadimitrakopoulou. (Video Program)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lung cancer.

    The past several years have seen an explosion in the emergence of new therapies that leverage the natural ability of the human body to attack and treat cancer. Known as immune-mediated therapies or cancer immunotherapies, these promising treatments are taking center stage at medical conferences and generating excitement all over the world. Perhaps the most exciting arena in this regard has been the development and assessment of a class of checkpoint inhibitors that inhibit PD-1 or PD-L1. To date, studies with these agents, alone and in combination with other agents, have demonstrated a high degree of activity with manageable toxicity. The availability of these novel compounds has rapidly upended traditional therapeutic sequencing and caused both shifts and rifts in clinical management algorithms, and a number of controversies and questions remain with regard to the current application of these agents in clinical practice.

    These video proceedings from a CME symposium held during the 2018 SITC Annual Meeting feature discussions with leading researchers with an expertise in lung cancer. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical oncologists, hematology-oncology fellows and other healthcare professionals with the optimal incorporation of immune checkpoint inhibitors in metastatic lung cancer.


    • Review research data documenting the safety and efficacy of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy for newly diagnosed metastatic nonsquamous non-small cell lung cancer (NSCLC), and use this information to guide up-front decision-making for these individuals.
    • Appraise recent Phase III data describing the activity and safety of combining an anti-PD-L1 antibody, anti-angiogenic therapy and chemotherapy for patients with newly diagnosed metastatic nonsquamous NSCLC, and determine the potential utility of this approach in clinical practice.
    • Describe available research data documenting the efficacy and safety associated with the use of an anti-PD-1/PD-L1 antibody in combination with platinum-based chemotherapy for patients with newly diagnosed metastatic squamous NSCLC, and evaluate the potential clinical and research implications of these findings.
    • Understand the biologic rationale for and published research data with the use of combinations targeting multiple immune checkpoints, and, where applicable, refer patients for ongoing trials or other related expanded access programs.
    • Consider emerging research data and available guideline recommendations informing the use of immune checkpoint inhibitors for patients with small cell lung cancer (SCLC).
    • Recall the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies for NSCLC and SCLC, and counsel appropriate patients about availability and participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Edward B Garon, MD, MS
    Associate Professor
    Director, Thoracic Oncology Program
    Jonsson Comprehensive Cancer Center
    David Geffen School of Medicine at UCLA
    Los Angeles, California

    Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Dynavax, Genentech, Iovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics, Novartis.

    Giuseppe Giaccone, MD, PhD
    Associate Director for Clinical Research
    Lombardi Comprehensive Cancer Center
    Professor of Medical Oncology and Pharmacology
    Georgetown University
    Director of Clinical Research
    MedStar Health Cancer Network’s Washington Region
    Washington, DC

    No relevant conflicts of interest to disclose.

    Roy S Herbst, MD, PhD
    Ensign Professor of Medicine
    Professor of Pharmacology
    Chief of Medical Oncology
    Director, Thoracic Oncology Research Program
    Associate Director for Translational Research
    Yale Comprehensive Cancer Center
    Yale School of Medicine
    New Haven, Connecticut

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Genentech, Lilly, Merck, NextCure Inc, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Lilly, Merck; Data and Safety Monitoring Board/Committee: Heat Biologics, Merck.

    Vali A Papadimitrakopoulou, MD
    Jay and Lori Eisenberg Distinguished Professor of Medicine
    Section Chief, Thoracic Medical Oncology
    Department of Thoracic/HN Medical Oncology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee and Consulting Agreements: AbbVie Inc, Araxes Pharma LLC, Arrys Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Exelixis Inc, F Hoffmann-La Roche, Janssen Biotech Inc, Lilly, Loxo Oncology, Merck, Nektar, Novartis, Roche Laboratories Inc, Takeda Oncology, Tesaro Inc, TRM Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Checkmate Pharmaceuticals, F Hoffmann-La Roche, Incyte Corporation, Janssen Biotech Inc, Lilly, Merck, Nektar, Novartis.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Genentech and Merck.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: December 2018
    Expiration date: December 2019

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):